跳转至内容
Merck
CN

L-029

Supelco

Lacosamide solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C13H18N2O3
化学文摘社编号:
分子量:
250.29
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in acetonitrile

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

CC(N[C@H](COC)C(NCC1=CC=CC=C1)=O)=O

InChI

1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

InChI key

VPPJLAIAVCUEMN-GFCCVEGCSA-N

相关类别

一般描述

A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, prescription monitoring or pharmaceutical research. Lacosamide is a new antiepileptic drug developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. The drug is marketed under the trade name Vimpat®.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vimpat is a registered trademark of Harris FRC Corporation

象形图

FlameExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

35.6 °F - closed cup

闪点(°C)

2 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Collin A Hovinga
IDrugs : the investigational drugs journal, 6(5), 479-485 (2003-06-06)
Schwarz Pharma, under license from Harris FRC, is developing SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain.
G McCleane et al.
Neuroscience letters, 352(2), 117-120 (2003-11-20)
The aim of the study is to establish if the putative anticonvulsant SPM 927 has an analgesic effect in human neuropathic pain and to assess its tolerability. This is an open label study of 25 adult human subjects with resistant
Molecule of the month. Lacosamide.
Drug news & perspectives, 17(10), 689-689 (2005-02-08)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持